Bioquell has been selected to supply the isolators for the NBMC, along with a system for fumigation of the cleanrooms
The UK Centre for Process Innovation (CPI) has announced that the new National Biologics Manufacturing Centre (NBMC) will be located in Darlington. The town was chosen based on excellent transport links, close proximity to existing pharmaceutical companies and relevant universities in the north of England in addition to growth opportunities within the Tees Valley Enterprise Zone.
Commenting on the new centre, Minister for Universities and Science David Willetts MP, said: 'The new National Biologics Manufacturing Centre will significantly increase the UK’s manufacturing capability in biologics, keeping us ahead in the global race and strengthening the UK’s position as the location of choice for life sciences companies.'
Following a detailed tender process, Bioquell has been selected to supply the isolators for the NBMC, along with a system for fumigation of the cleanrooms within the new facility.
The decontamination specialist will be supplying two variants of the Bioquell QUBE, a modular isolator system with integrated rapid decontamination technology. In addition to the latest generation of isolator technology, it will also supply a Bioquell Z-2 system which will provide rapid and safe decontamination of the four cleanroom zones in the new building.
Bioquell project teams are currently working with CPI staff to ensure problem-free installation of the new equipment which is scheduled for delivery in April 2015.
Commenting on the project, Dr Tim Flanagan, head of Life Sciences for Bioquell, said: 'We are very pleased to be able to partner with the National Biologics Manufacturing Centre to ensure the most modern and efficient technology is available for such an important investment in biologics manufacturing in the UK.'